Related Experiment Video
Updated: Jul 22, 2026

Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis
Published on: July 12, 2011
[Inhibitory effects of new-breviscapine on thrombosis in vivo]
Abstract:
New-Breviscapine is an anti-platelet compound with some kinds of salts extracted from a Chinese herb Erigeron breviscapus. In aortic thrombus formation in rabbits, the platelet 5-HT release reaction and platelet destruction could be reduced by the compound, meanwhile aortic thrombosis was inhibited with a clear correlation between drug dosage and its efficacy. It was shown that new-breviscapine could inhibit the production of TXB2 and 6-keto-PGF1 alpha by platelets and endothelial cells respectively. The data suggest that new-breviscapine has a significant inhibitory effect on thrombus formation in vivo through suppression of platelet functions.
Related Concept Videos
Intracellular Signaling Affects Focal Adhesions
Some...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care

